Sanofi Pulls Global Filings For Semuloparin As VTE Prophylaxis In Cancer Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
The company decided to withdraw all applications for approval of the low molecular weight heparin following comments from regulatory agencies. FDA and its Oncologic Drugs Advisory Committee had taken a negative view of the semuloparin NDA, believing Sanofi failed to identify an appropriate population of chemotherapy patients.
You may also be interested in...
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works
FDA Commissioner Robert Califf tells House appropriations subcommittee chair the agency will 'consider any information that may be available' on off-label use of puberty blockers for gender dysphoria before making a regulatory decision.
ADHD Drugs: FDA Commissioner Blames Inappropriate Prescribing For Shortages
ADHD drug shortages may have resulted from industry reticence to fill DEA quotas, as well as a 'heavy element of professional responsibility' with off-label prescribing, Robert Califf told a House appropriations subcommittee.